vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Bristow Group Inc. (VTOL). Click either name above to swap in a different company.
Bristow Group Inc. is the larger business by last-quarter revenue ($377.3M vs $281.3M, roughly 1.3× Guardant Health, Inc.). Bristow Group Inc. runs the higher net margin — 4.9% vs -45.7%, a 50.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 6.7%). Bristow Group Inc. produced more free cash flow last quarter ($47.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Bristow Helicopters Limited is a British civil helicopter operator originally based at Aberdeen Airport, Scotland, which is currently a part of the U.S.-based Bristow Group which in turn has its corporate headquarters in Houston, Texas, U.S. In 2020, Bristow Group was merged with Era Helicopters, a large U.S.-based commercial helicopter operator that was previously a division of Era Aviation, with the two companies then continuing to use the Bristow name.
GH vs VTOL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $377.3M |
| Net Profit | $-128.5M | $18.4M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 8.5% |
| Net Margin | -45.7% | 4.9% |
| Revenue YoY | 39.4% | 6.7% |
| Net Profit YoY | -15.8% | -42.1% |
| EPS (diluted) | $-1.01 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $377.3M | ||
| Q3 25 | $265.2M | $386.3M | ||
| Q2 25 | $232.1M | $376.4M | ||
| Q1 25 | $203.5M | $350.5M | ||
| Q4 24 | $201.8M | $353.5M | ||
| Q3 24 | $191.5M | $365.1M | ||
| Q2 24 | $177.2M | $359.7M | ||
| Q1 24 | $168.5M | $337.1M |
| Q4 25 | $-128.5M | $18.4M | ||
| Q3 25 | $-92.7M | $51.5M | ||
| Q2 25 | $-99.9M | $31.7M | ||
| Q1 25 | $-95.2M | $27.4M | ||
| Q4 24 | $-111.0M | $31.8M | ||
| Q3 24 | $-107.8M | $28.2M | ||
| Q2 24 | $-102.6M | $28.2M | ||
| Q1 24 | $-115.0M | $6.6M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 8.5% | ||
| Q3 25 | -37.3% | 13.1% | ||
| Q2 25 | -45.9% | 11.3% | ||
| Q1 25 | -54.6% | 9.6% | ||
| Q4 24 | -62.4% | 9.0% | ||
| Q3 24 | -61.3% | 9.1% | ||
| Q2 24 | -56.8% | 12.4% | ||
| Q1 24 | -59.2% | 6.8% |
| Q4 25 | -45.7% | 4.9% | ||
| Q3 25 | -35.0% | 13.3% | ||
| Q2 25 | -43.0% | 8.4% | ||
| Q1 25 | -46.8% | 7.8% | ||
| Q4 24 | -55.0% | 9.0% | ||
| Q3 24 | -56.3% | 7.7% | ||
| Q2 24 | -57.9% | 7.8% | ||
| Q1 24 | -68.2% | 2.0% |
| Q4 25 | $-1.01 | $0.61 | ||
| Q3 25 | $-0.74 | $1.72 | ||
| Q2 25 | $-0.80 | $1.07 | ||
| Q1 25 | $-0.77 | $0.92 | ||
| Q4 24 | $-0.90 | $1.07 | ||
| Q3 24 | $-0.88 | $0.95 | ||
| Q2 24 | $-0.84 | $0.96 | ||
| Q1 24 | $-0.94 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $286.2M |
| Total DebtLower is stronger | $1.5B | $671.5M |
| Stockholders' EquityBook value | $-99.3M | $1.1B |
| Total Assets | $2.0B | $2.3B |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $286.2M | ||
| Q3 25 | $580.0M | $245.5M | ||
| Q2 25 | $629.1M | $251.8M | ||
| Q1 25 | $698.6M | $191.1M | ||
| Q4 24 | $525.5M | $247.5M | ||
| Q3 24 | $585.0M | $200.3M | ||
| Q2 24 | $933.7M | $178.6M | ||
| Q1 24 | $1.0B | $140.6M |
| Q4 25 | $1.5B | $671.5M | ||
| Q3 25 | $1.1B | $675.0M | ||
| Q2 25 | $1.1B | $705.2M | ||
| Q1 25 | $1.1B | $701.9M | ||
| Q4 24 | $1.1B | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M | ||
| Q1 24 | — | $544.1M |
| Q4 25 | $-99.3M | $1.1B | ||
| Q3 25 | $-354.5M | $1.0B | ||
| Q2 25 | $-305.5M | $984.4M | ||
| Q1 25 | $-250.8M | $931.7M | ||
| Q4 24 | $-139.6M | $891.7M | ||
| Q3 24 | $-60.1M | $899.2M | ||
| Q2 24 | $-1.6M | $849.1M | ||
| Q1 24 | $68.3M | $820.7M |
| Q4 25 | $2.0B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.5B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.6B | $2.0B | ||
| Q1 24 | $1.7B | $1.9B |
| Q4 25 | — | 0.63× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $76.9M |
| Free Cash FlowOCF − Capex | $-54.2M | $47.8M |
| FCF MarginFCF / Revenue | -19.3% | 12.7% |
| Capex IntensityCapex / Revenue | 9.9% | 7.7% |
| Cash ConversionOCF / Net Profit | — | 4.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $56.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $76.9M | ||
| Q3 25 | $-35.4M | $23.1M | ||
| Q2 25 | $-60.3M | $99.0M | ||
| Q1 25 | $-62.7M | $-603.0K | ||
| Q4 24 | $-64.5M | $51.1M | ||
| Q3 24 | $-51.1M | $66.0M | ||
| Q2 24 | $-94.0M | $33.7M | ||
| Q1 24 | $-30.3M | $26.7M |
| Q4 25 | $-54.2M | $47.8M | ||
| Q3 25 | $-45.8M | $-6.2M | ||
| Q2 25 | $-65.9M | $67.4M | ||
| Q1 25 | $-67.1M | $-52.7M | ||
| Q4 24 | $-83.4M | $-32.4M | ||
| Q3 24 | $-55.3M | $9.0M | ||
| Q2 24 | $-99.1M | $-16.7M | ||
| Q1 24 | $-37.2M | $-37.9M |
| Q4 25 | -19.3% | 12.7% | ||
| Q3 25 | -17.3% | -1.6% | ||
| Q2 25 | -28.4% | 17.9% | ||
| Q1 25 | -33.0% | -15.0% | ||
| Q4 24 | -41.3% | -9.2% | ||
| Q3 24 | -28.9% | 2.5% | ||
| Q2 24 | -55.9% | -4.6% | ||
| Q1 24 | -22.1% | -11.2% |
| Q4 25 | 9.9% | 7.7% | ||
| Q3 25 | 3.9% | 7.6% | ||
| Q2 25 | 2.4% | 8.4% | ||
| Q1 25 | 2.2% | 14.9% | ||
| Q4 24 | 9.4% | 23.6% | ||
| Q3 24 | 2.2% | 15.6% | ||
| Q2 24 | 2.9% | 14.0% | ||
| Q1 24 | 4.1% | 19.2% |
| Q4 25 | — | 4.17× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 3.12× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 4.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
